{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:43:34Z","timestamp":1770511414544,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.msard.2019.07.026","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:50:49Z","timestamp":1565121049000},"page":"270-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab"],"prefix":"10.1016","volume":"35","author":[{"given":"Clara","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2019.07.026_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1352458514549398","article-title":"Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis","volume":"21","author":"Artung","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.07.026_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2017.12.009","article-title":"Hepatic microabscesses during CMV reactivation in multiple sclerosis patient after alemtuzumab treatment","volume":"20","author":"Barone","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.07.026_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2018.09.031","article-title":"Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis","volume":"27","author":"Buonomo","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.07.026_bib0004","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1352458516688350","article-title":"Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab","volume":"23","author":"Clerico","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.07.026_bib0005","unstructured":"Genzyme. Lemtrada summary of products characteristics2016. Available at:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EIPAR\/lemtrada."},{"key":"10.1016\/j.msard.2019.07.026_bib0006","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/ajt.14192","article-title":"Preventive strategies against cytomegalovirus and incidence of \u03b1-herpesvirus infections in solid organ transplant recipients: a nationwide cohort study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am. J. Transplant"},{"issue":"13","key":"10.1016\/j.msard.2019.07.026_bib0007","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"25","author":"Moreton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2019.07.026_bib0008","doi-asserted-by":"crossref","unstructured":"O\u00b4Brien S.M., Keating M.J., Mocarski E.S.. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma7(2); 125\u2013130.","DOI":"10.3816\/CLM.2006.n.049"},{"key":"10.1016\/j.msard.2019.07.026_bib0009","first-page":"1","article-title":"Simultaneous CMV and listeria infection following alemtuzumab treatment for multiple sclerosis","volume":"92","author":"Pappola","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.07.026_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2017.03.001","article-title":"Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis","volume":"14","author":"Yann","year":"2017","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:35Z","timestamp":1761900455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819303207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":10,"alternative-id":["S2211034819303207"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.07.026","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}